02-11-11

Notas del editor

• #2: Fsfshfksh
• #24: Reference: Varadarajan P, et al. Eur J Cardiothorac Surg . 2006;30:722-727.      
• #25: Pre-closing with ProStar™ No cardiac assistance ProStar - Source: Grube, et al. Progress and Current Status of Percutaneous AVR: Results of three device generations of the CRS, Dec 2008 , Circ Cardivasc Intervent
• #28:       
• #29: Key Message: There were sustained improvements in hemodynamic performance through 2 years. The CoreValve ® System EU Safety and Performance Study also investigated valve performance (including transvalvular gradient and valve regurgitation grade as measured by control Doppler echocardiography as well as effective prosthetic valve orifice area) over time, up to 2 years post implantation. In all measurements, valve performance showed a marked improvement at implantation (as a result of the new valve), and these analyses demonstrated that for those patients with evaluable echo data, the mean outcomes of valve performances across time points remained relatively stable to 2 years. For example, the available mean effective orifice area for all groups combined increased from 0.72 cm 2 to 1.81 cm 2 at discharge and ranged from 1.71 cm 2 to 1.81 cm 2 between discharge and 2 years post operative. It is notable that none of the follow-up readings of aortic regurgitation from the Echo Core Lab were grade 2 or higher at any time point in any of the risk assessment groups. Reference: Buellesfeld L, et al. J Am Coll Cardiol . 2011;57:1650-1657.
• #30: Key Message: There was a significant and sustained NYHA functional heart class improvement at 2 years. This slide illustrates the change in functional status over time for the combined cohort as well as for the 3 risk groups at discharge, 1 month, 6 months, 1 year, and 3 years post implantation. In the figure, levels refers to NYHA functional classes (I to IV). Although the sample sizes vary among groups and the total number of evaluable patients decreases over time, a majority of patients maintain an improved functional status at every time point. Reference: Gerckens U. Stable durability and effectiveness at 2 years with CoreValve ® transcatheter aortic valve. Presented at: EuroPCR; May 17-20, 2011; Paris, France.
• #31: Key Message: There were clinically acceptable rates of aortic regurgitation at 2 years. CoreValve ® System performance, including transvalvular gradient and valve regurgitation grade, was measured over time, up to 2 years post implantation. It is notable that none of the follow-up readings of aortic regurgitation from the Echo Core Lab were grade 2 or higher at any time point in any of the risk assessment groups. Reference: Gerckens U. Stable durability and effectiveness at 2 years with CoreValve ® transcatheter aortic valve. Presented at: EuroPCR; May 17-20, 2011; Paris, France.